{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T16:51:07Z","timestamp":1791305467032,"version":"4.3.1"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100022416","name":"Center for Drug Evaluation and Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100022416","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharm Res"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s11095-026-04153-w","type":"journal-article","created":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T22:48:49Z","timestamp":1785365329000},"page":"3245-3261","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Development of an In Vitro Permeation Test Framework For Naloxone Hydrochloride Intranasal Spray: Establishing IVIVR for Bioequivalence Assessment"],"prefix":"10.1007","volume":"43","author":[{"given":"Tasmin Ara","family":"Sultana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manar","family":"Al-Ghabeish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Chopski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross","family":"Walenga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diaa","family":"Shakleya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan","family":"Newman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Ashraf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5830-4213","authenticated-orcid":false,"given":"Ahmed","family":"Zidan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,30]]},"reference":[{"key":"4153_CR1","unstructured":"National Center for Biotechnology Information. PubChem Compound Summary for CID 5284596, Naloxone. 2025. Available from: \nhttps:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Naloxone. Accessed\u00a06 Jul 2026."},{"issue":"13","key":"4153_CR2","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1007\/s40265-019-01154-5","volume":"79","author":"J Strang","year":"2019","unstructured":"Strang J, McDonald R, Campbell G, Degenhardt L, Nielsen S, Ritter A, et al. Take-Home Naloxone for the Emergency Interim Management of Opioid Overdose: The Public Health Application of an Emergency Medicine. Drugs. 2019;79(13):1395\u2013418.","journal-title":"Drugs"},{"key":"4153_CR3","unstructured":"World Health Organization. Opioid overdose 2025 [updated 08\/29\/2025. Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/opioid-overdose.\u00a0Accessed 6 Jul 2026."},{"key":"4153_CR4","unstructured":"World Health Organization. Electronic Model List of Essential Medicines 2025 [updated 09\/2025. Available from: https:\/\/list.essentialmeds.org\/. Accessed 6 Jul 2026."},{"issue":"8","key":"4153_CR5","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1002\/jcph.1401","volume":"59","author":"PA Krieter","year":"2019","unstructured":"Krieter PA, Chiang CN, Gyaw S, McCann DJ. Comparison of the Pharmacokinetic Properties of Naloxone Following the Use of FDA-Approved Intranasal and Intramuscular Devices Versus a Common Improvised Nasal Naloxone Device. J Clin Pharmacol. 2019;59(8):1078\u201384.","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"4153_CR6","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1111\/add.14033","volume":"113","author":"R McDonald","year":"2018","unstructured":"McDonald R, Lorch U, Woodward J, Bosse B, Dooner H, Mundin G, et al. Pharmacokinetics of concentrated naloxone nasal spray for opioid overdose reversal: Phase I healthy volunteer study. Addiction. 2018;113(3):484\u201393.","journal-title":"Addiction"},{"key":"4153_CR7","doi-asserted-by":"publisher","unstructured":"Tyllesk\u00e4r I, Skulberg AK, Nilsen T, Skarra S, Dale O. Naloxone nasal spray\u2014bioavailability and absorption pattern in a phase 1 study. Tidsskr Nor Laegeforen. 2019;139(13). https:\/\/doi.org\/10.4045\/tidsskr.19.0162.","DOI":"10.4045\/tidsskr.19.0162"},{"issue":"5","key":"4153_CR8","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1007\/s00228-016-2191-1","volume":"73","author":"I Tylleskar","year":"2017","unstructured":"Tylleskar I, Skulberg AK, Nilsen T, Skarra S, Jansook P, Dale O. Pharmacokinetics of a new, nasal formulation of naloxone. Eur J Clin Pharmacol. 2017;73(5):555\u201362.","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"4153_CR9","doi-asserted-by":"publisher","first-page":"709","DOI":"10.4155\/tde.14.41","volume":"5","author":"PG Djupesland","year":"2014","unstructured":"Djupesland PG, Messina JC, Mahmoud RA. The nasal approach to delivering treatment for brain diseases: an anatomic, physiologic, and delivery technology overview. Ther Deliv. 2014;5(6):709\u201333.","journal-title":"Ther Deliv"},{"key":"4153_CR10","unstructured":"U.S. Food and Drug Administration. Draft guidance on naloxone hydrochloride: nasal metered spray. Product-specific guidance for generic drug development [Internet]. Silver Spring (MD): U.S. Food and Drug Administration; 2024. Unique Agency Identifier: PSG_208969. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/psg\/PSG_208969.pdf. Accessed 6 Jul 2026."},{"issue":"18","key":"4153_CR11","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/S1359-6446(02)02452-2","volume":"7","author":"P Arora","year":"2002","unstructured":"Arora P, Sharma S, Garg S. Permeability issues in nasal drug delivery. Drug Discov Today. 2002;7(18):967\u201375.","journal-title":"Drug Discov Today"},{"key":"4153_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebr.2022.100581","volume":"21","author":"S Chung","year":"2023","unstructured":"Chung S, Peters JM, Detyniecki K, Tatum W, Rabinowicz AL, Carrazana E. The nose has it: opportunities and challenges for intranasal drug administration for neurologic conditions including seizure clusters. Epilepsy Behav Rep. 2023;21:100581.","journal-title":"Epilepsy Behav Rep"},{"issue":"1\u20132","key":"4153_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijpharm.2007.03.025","volume":"337","author":"HR Costantino","year":"2007","unstructured":"Costantino HR, Illum L, Brandt G, Johnson PH, Quay SC. Intranasal delivery: physicochemical and therapeutic aspects. Int J Pharm. 2007;337(1\u20132):1\u201324.","journal-title":"Int J Pharm"},{"key":"4153_CR14","unstructured":"Costantino HR, Sileno AP, Johnson PH. Pharmacokinetic attributes of intranasal delivery: case studies and new opportunities. In: Nasal drug delivery on drug delivery magazine [Internet]. Issue No. 03. Furness Publishing; 2005, pp 8\u201311. Available from: https:\/\/ondrugdelivery.com\/magazines\/nasal-drug-delivery\/. Accessed 6 Jul 2026."},{"issue":"1","key":"4153_CR15","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1007\/s13346-012-0108-9","volume":"3","author":"PG Djupesland","year":"2013","unstructured":"Djupesland PG. Nasal drug delivery devices: characteristics and performance in a clinical perspective-a review. Drug Deliv Transl Res. 2013;3(1):42\u201362.","journal-title":"Drug Deliv Transl Res"},{"issue":"6","key":"4153_CR16","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1208\/s12249-025-03171-y","volume":"26","author":"S Lobo","year":"2025","unstructured":"Lobo S, Xi Z, Das D, Hadzimichalis NM, Creek JA. Intranasal Delivery: Formulation Factors and Insights Into User Experience. AAPS PharmSciTech. 2025;26(6):179.","journal-title":"AAPS PharmSciTech"},{"issue":"1\u20132","key":"4153_CR17","first-page":"157","volume":"29","author":"MT Vidgren","year":"1998","unstructured":"Vidgren MT, Kublik H. Nasal delivery systems and their effect on deposition and absorption. Adv Drug Deliv Rev. 1998;29(1\u20132):157\u201377.","journal-title":"Adv Drug Deliv Rev"},{"key":"4153_CR18","unstructured":"U.S. Food and Drug Administration. Extended release oral dosage forms: development, evaluation, and application of in vitro\/in vivo correlations. In: Guidance for industry [Internet]. Rockville (MD): U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research; 1997. Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/extended-release-oral-dosage-forms-development-evaluation-and-application-vitroin-in-vivo-correlations. Accessed 6 Jul 2026."},{"key":"4153_CR19","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/j.jconrel.2015.09.052","volume":"219","author":"J Shen","year":"2015","unstructured":"Shen J, Burgess DJ. In vitro-in vivo correlation for complex non-oral drug products: Where do we stand? J Control Release. 2015;219:644\u201351.","journal-title":"J Control Release"},{"issue":"3","key":"4153_CR20","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1208\/s12248-013-9494-2","volume":"15","author":"BV Li","year":"2013","unstructured":"Li BV, Jin F, Lee SL, Bai T, Chowdhury B, Caramenico HT, et al. Bioequivalence for locally acting nasal spray and nasal aerosol products: standard development and generic approval. AAPS J. 2013;15(3):875\u201383.","journal-title":"AAPS J"},{"key":"4153_CR21","doi-asserted-by":"publisher","first-page":"2424","DOI":"10.1016\/j.csbj.2025.05.036","volume":"27","author":"S Park","year":"2025","unstructured":"Park S, Song SS, Jung W, Yun HY, Lee S, Kang SW, et al. Mechanistic in vitro-in vivo extrapolation (IVIVE) approach using a biomimetic in vitro system for the prediction of hepatic clearance. Comput Struct Biotechnol J. 2025;27:2424\u201333.","journal-title":"Comput Struct Biotechnol J"},{"issue":"2","key":"4153_CR22","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.ejpb.2005.02.010","volume":"60","author":"B Forbes","year":"2005","unstructured":"Forbes B, Ehrhardt C. Human respiratory epithelial cell culture for drug delivery applications. Eur J Pharm Biopharm. 2005;60(2):193\u2013205.","journal-title":"Eur J Pharm Biopharm"},{"issue":"7","key":"4153_CR23","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1007\/s11095-006-0255-0","volume":"23","author":"CI Grainger","year":"2006","unstructured":"Grainger CI, Greenwell LL, Lockley DJ, Martin GP, Forbes B. Culture of Calu-3 cells at the air interface provides a representative model of the airway epithelial barrier. Pharm Res. 2006;23(7):1482\u201390.","journal-title":"Pharm Res"},{"issue":"6","key":"4153_CR24","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1016\/j.jaci.2020.04.010","volume":"145","author":"PW Hellings","year":"2020","unstructured":"Hellings PW, Steelant B. Epithelial barriers in allergy and asthma. J Allergy Clin Immunol. 2020;145(6):1499\u2013509.","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"4153_CR25","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1208\/s12249-019-1452-6","volume":"20","author":"HJ Hsu","year":"2019","unstructured":"Hsu HJ, Yang Y, Pavuluri V, Abraham C, Naraharisetti SB, Ashraf M, et al. Effect of Formulation Variables on the Nasal Permeability and Stability of Naloxone Intranasal Formulations. AAPS PharmSciTech. 2019;20(6):232.","journal-title":"AAPS PharmSciTech"},{"key":"4153_CR26","unstructured":"VITROCELL Systems GmbH. VITROCELL\u00ae Cloud Alpha 12: advanced in vitro exposure systems [product brochure, Internet]. Waldkirch: VITROCELL Systems GmbH; 2023. Available from: https:\/\/www.vitrocell.com\/docs\/EN\/files\/assets\/common\/downloads\/publication.pdf. Accessed 6 Jul 2026."},{"issue":"1","key":"4153_CR27","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s12989-020-00376-w","volume":"17","author":"Y Ding","year":"2020","unstructured":"Ding Y, Weindl P, Lenz AG, Mayer P, Krebs T, Schmid O. Quartz crystal microbalances (QCM) are suitable for real-time dosimetry in nanotoxicological studies using VITROCELL(R)Cloud cell exposure systems. Part Fibre Toxicol. 2020;17(1):44.","journal-title":"Part Fibre Toxicol"},{"key":"4153_CR28","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.addr.2020.09.002","volume":"170","author":"S Le Guellec","year":"2021","unstructured":"Le Guellec S, Ehrmann S, Vecellio L. In vitro - in vivo correlation of intranasal drug deposition. Adv Drug Deliv Rev. 2021;170:340\u201352.","journal-title":"Adv Drug Deliv Rev"},{"issue":"4","key":"4153_CR29","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1165\/rcmb.2013-0479OC","volume":"51","author":"AG Lenz","year":"2014","unstructured":"Lenz AG, Stoeger T, Cei D, Schmidmeir M, Semren N, Burgstaller G, et al. Efficient bioactive delivery of aerosolized drugs to human pulmonary epithelial cells cultured in air-liquid interface conditions. Am J Respir Cell Mol Biol. 2014;51(4):526\u201335.","journal-title":"Am J Respir Cell Mol Biol"},{"key":"4153_CR30","doi-asserted-by":"publisher","unstructured":"Leroux MM, Hocquel R, Bourge K, Kokot B, Kokot H, Kokli\u010d T, \u0160trancar J, Ding Y, Kumar P, Schmid O, Rihn BH, Ferrari L, Joubert O. Aerosol\u2013cell exposure system applied to semi-adherent cells for aerosolization of lung surfactant and nanoparticles followed by high quality RNA extraction. Nanomaterials (Basel). 2022;12(8):1362. https:\/\/doi.org\/10.3390\/nano12081362.","DOI":"10.3390\/nano12081362"},{"key":"4153_CR31","unstructured":"PermeGear. In-Line Cells 2025 [Available from: https:\/\/permegear.com\/in-line-cells\/. Accessed 6 Jul 2026."},{"issue":"9","key":"4153_CR32","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1007\/s11095-017-2189-0","volume":"34","author":"SH Shin","year":"2017","unstructured":"Shin SH, Ghosh P, Newman B, Hammell DC, Raney SG, Hassan HE, et al. On the Road to Development of an in Vitro Permeation Test (IVPT) Model to Compare Heat Effects on Transdermal Delivery Systems: Exploratory Studies with Nicotine and Fentanyl. Pharm Res. 2017;34(9):1817\u201330.","journal-title":"Pharm Res"},{"issue":"3","key":"4153_CR33","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/S0168-3659(00)00306-0","volume":"69","author":"M Cordoba-Diaz","year":"2000","unstructured":"Cordoba-Diaz M, Nova M, Elorza B, Cordoba-Diaz D, Chantres JR, Cordoba-Borrego M. Validation protocol of an automated in-line flow-through diffusion equipment for in vitro permeation studies. J Control Release. 2000;69(3):357\u201367.","journal-title":"J Control Release"},{"key":"4153_CR34","doi-asserted-by":"publisher","first-page":"46","DOI":"10.14227\/DT180411P46","volume":"18","author":"N Fotaki","year":"2011","unstructured":"Fotaki N. Flow-through cell apparatus (USP apparatus 4): Operation and features. Dissolut Technol. 2011;18:46\u20139.","journal-title":"Dissolut Technol"},{"key":"4153_CR35","doi-asserted-by":"publisher","first-page":"117366","DOI":"10.1016\/j.jpba.2026.117366","volume":"272","author":"TA Sultana","year":"2026","unstructured":"Sultana TA, Shakleya D, Brown DG, Faustino PJ, Ashraf M, Zidan A. Biopharmaceutical assessment of naloxone permeation through human respiratory epithelial tissues: A chromatographic-mass spectrometric approach with cloud based aerosol dosing and delivery. J Pharm Biomed Anal. 2026;272:117366.","journal-title":"J Pharm Biomed Anal"},{"key":"4153_CR36","first-page":"233","volume":"188","author":"S Tavelin","year":"2002","unstructured":"Tavelin S, Grasjo J, Taipalensuu J, Ocklind G, Artursson P. Applications of epithelial cell culture in studies of drug transport. Methods Mol Biol. 2002;188:233\u201372.","journal-title":"Methods Mol Biol"},{"issue":"4","key":"4153_CR37","doi-asserted-by":"publisher","first-page":"104215","DOI":"10.1016\/j.xphs.2026.104215","volume":"115","author":"DG Brown","year":"2026","unstructured":"Brown DG, Sultana TA, Faustino P, Shakleya D. Determination of naloxone and its impurities in a vaporized matrix by LC-MS\/MS: Application of an in vitro surrogate model platform to assess in vivo permeation and risk associated with vaping opioids. J Pharm Sci. 2026;115(4):104215.","journal-title":"J Pharm Sci"},{"issue":"10","key":"4153_CR38","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1002\/jcph.759","volume":"56","author":"P Krieter","year":"2016","unstructured":"Krieter P, Chiang N, Gyaw S, Skolnick P, Crystal R, Keegan F, et al. Pharmacokinetic properties and human use characteristics of an FDA-approved intranasal naloxone product for the treatment of opioid overdose. J Clin Pharmacol. 2016;56(10):1243\u201353.","journal-title":"J Clin Pharmacol"},{"key":"4153_CR39","unstructured":"European Medicines Agency. Guideline on the investigation of bioequivalence [Internet]. London: European Medicines Agency; 2010. CPMP\/EWP\/QWP\/1401\/98 Rev. 1\/Corr**. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-investigation-bioequivalence-rev1_en.pdf. Accessed 6 Jul 2026."},{"issue":"3","key":"4153_CR40","doi-asserted-by":"publisher","first-page":"376","DOI":"10.18433\/J3VC8J","volume":"15","author":"RK Verbeeck","year":"2012","unstructured":"Verbeeck RK, Musuamba FT. The revised EMA guideline for the investigation of bioequivalence for immediate release oral formulations with systemic action. J Pharm Pharm Sci. 2012;15(3):376\u201388.","journal-title":"J Pharm Pharm Sci"},{"key":"4153_CR41","unstructured":"European Medicines Agency. Guideline on quality of oral modified-release products [Internet]. London: European Medicines Agency; 2014. EMA\/CHMP\/QWP\/428693\/2013. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-quality-oral-modified-release-products_en.pdf. Accessed 6 Jul 2026."},{"key":"4153_CR42","doi-asserted-by":"publisher","unstructured":"Rath S, Kanfer I. In vitro\u2013in vivo correlations (IVIVC) for predicting the clinical performance of metronidazoletopical creams intended for local action. Pharmaceutics. 2023;15(1):268. https:\/\/doi.org\/10.3390\/pharmaceutics15010268.","DOI":"10.3390\/pharmaceutics15010268"},{"issue":"1","key":"4153_CR43","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.ijpharm.2011.01.010","volume":"418","author":"Y Lu","year":"2011","unstructured":"Lu Y, Kim S, Park K. In vitro-in vivo correlation: perspectives on model development. Int J Pharm. 2011;418(1):142\u20138.","journal-title":"Int J Pharm"},{"issue":"2\u20133","key":"4153_CR44","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.agsy.2005.11.004","volume":"89","author":"LO Tedeschi","year":"2006","unstructured":"Tedeschi LO. Assessment of the adequacy of mathematical models. Agric Syst. 2006;89(2\u20133):225\u201347.","journal-title":"Agric Syst"},{"key":"4153_CR45","unstructured":"Onose E. Arize AI, Inc. 2023. [cited 2025]. Available from: https:\/\/arize.com\/blog-course\/r-squared-understanding-the-coefficient-of-determination\/. Accessed 6 Jul 2026."},{"issue":"6","key":"4153_CR46","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1208\/s12248-016-9966-2","volume":"18","author":"S Suarez-Sharp","year":"2016","unstructured":"Suarez-Sharp S, Li M, Duan J, Shah H, Seo P. Regulatory Experience with In Vivo In Vitro Correlations (IVIVC) in New Drug Applications. AAPS J. 2016;18(6):1379\u201390.","journal-title":"AAPS J"},{"key":"4153_CR47","unstructured":"OEN Manifold. Steps for Multivariate Analysis and Results 2025 [Available from: https:\/\/manifold.open.umn.edu\/read\/chapter-7-steps-for-multivariate-analysis-and-results.\u00a0Accessed 6 Jul 2026."},{"issue":"16","key":"4153_CR48","volume":"12","author":"A Zaki","year":"2023","unstructured":"Zaki A, M\u00e9twalli A, Aly MH, Badawi WK. 5G and beyond: channel classification enhancement using VIF-driven preprocessing and machine learning. Electronics (Basel). 2023;12(16):3496.","journal-title":"Electronics (Basel)"},{"key":"4153_CR49","doi-asserted-by":"publisher","unstructured":"Murray L, Nguyen H, Lee Y-F, Remmenga MD, Smith DW. Variance inflation factors in regression models with dummy variables. In: Proceedings of the 24th annual conference on applied statistics in agriculture [Internet]. Manhattan (KS): Kansas State University, New Prairie Press; 2012. pp. 161\u2013177. https:\/\/doi.org\/10.4148\/2475-7772.1034. Available from: https:\/\/newprairiepress.org\/agstatconference\/2012\/proceedings\/12. Accessed 6 Jul 2026.","DOI":"10.4148\/2475-7772.1034"},{"key":"4153_CR50","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1002\/jps.2600531126","volume":"53","author":"JG Wagner","year":"1964","unstructured":"Wagner JG, Nelson E. Kinetic Analysis of Blood Levels and Urinary Excretion in the Absorptive Phase after Single Doses of Drug. J Pharm Sci. 1964;53:1392\u2013403.","journal-title":"J Pharm Sci"},{"key":"4153_CR51","unstructured":"U.S. Food and Drug Administration. M10 bioanalytical method validation and study sample analysis. Guidance for industry [Internet]. Silver Spring (MD): U.S. Food and Drug Administration; 2022 Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/m10-bioanalytical-method-validation-and-study-sample-analysis. Accessed 6 Jul 2026."},{"key":"4153_CR52","unstructured":"Aerogen, Inc. Aeroneb\u00ae Lab Nebulizer System Instruction Manual [Internet]. Galway, Ireland: Aerogen, Inc.; 2004. Part No.: AG-AL1010 Rev. C. Available from: https:\/\/www.kentscientific.com\/wp-content\/uploads\/2025\/10\/Aeroneb-Lab-User-Manual.pdf. Accessed 6 Jul 2026."},{"issue":"1","key":"4153_CR53","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1002\/med.20140","volume":"29","author":"MM Bailey","year":"2009","unstructured":"Bailey MM, Berkland CJ. Nanoparticle formulations in pulmonary drug delivery. Med Res Rev. 2009;29(1):196\u2013212.","journal-title":"Med Res Rev"},{"issue":"1","key":"4153_CR54","doi-asserted-by":"publisher","first-page":"9150","DOI":"10.1038\/s41598-020-65383-5","volume":"10","author":"A Brostrom","year":"2020","unstructured":"Brostrom A, Kling KI, Hougaard KS, Molhave K. Complex Aerosol Characterization by Scanning Electron Microscopy Coupled with Energy Dispersive X-ray Spectroscopy. Sci Rep. 2020;10(1):9150.","journal-title":"Sci Rep"},{"issue":"15","key":"4153_CR55","doi-asserted-by":"publisher","first-page":"5667","DOI":"10.1021\/es703075q","volume":"42","author":"M Savi","year":"2008","unstructured":"Savi M, Kalberer M, Lang D, Ryser M, Fierz M, Gaschen A, et al. A novel exposure system for the efficient and controlled deposition of aerosol particles onto cell cultures. Environ Sci Technol. 2008;42(15):5667\u201374.","journal-title":"Environ Sci Technol"},{"key":"4153_CR56","doi-asserted-by":"publisher","unstructured":"Tanis-Kanbur MB, Peinador RI, Calvo JI, Hern\u00e1ndez A, Chew JW. Porosimetric membrane characterization techniques: a review. J Membr Sci. 2021;619:118750. https:\/\/doi.org\/10.1016\/j.memsci.2020.118750.","DOI":"10.1016\/j.memsci.2020.118750"},{"issue":"5","key":"4153_CR57","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1007\/s11095-007-9475-1","volume":"25","author":"R Vehring","year":"2008","unstructured":"Vehring R. Pharmaceutical particle engineering via spray drying. Pharm Res. 2008;25(5):999\u20131022.","journal-title":"Pharm Res"},{"issue":"24","key":"4153_CR58","doi-asserted-by":"publisher","first-page":"18621","DOI":"10.1021\/la1039893","volume":"26","author":"J Drelich","year":"2010","unstructured":"Drelich J, Chibowski E. Superhydrophilic and superwetting surfaces: definition and mechanisms of control. Langmuir. 2010;26(24):18621\u20133.","journal-title":"Langmuir"},{"issue":"3","key":"4153_CR59","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1021\/acs.est.0c05454","volume":"55","author":"H Chang","year":"2021","unstructured":"Chang H, Liu B, Zhang Z, Pawar R, Yan Z, Crittenden JC, et al. A critical review of membrane wettability in membrane distillation from the perspective of interfacial interactions. Environ Sci Technol. 2021;55(3):1395\u2013418.","journal-title":"Environ Sci Technol"},{"key":"4153_CR60","doi-asserted-by":"publisher","unstructured":"Gieszinger P, Kiss T, Szab\u00f3-R\u00e9v\u00e9sz P, Ambrus R. The development of an in vitro horizontal diff us ion cell to monitor nasal powder penetration inline. Pharmaceutics. 2021;13(6):809. https:\/\/doi.org\/10.3390\/pharmaceutics13060809.","DOI":"10.3390\/pharmaceutics13060809"},{"key":"4153_CR61","doi-asserted-by":"publisher","unstructured":"Inoue D, Yamashita A, To H. Development of in vitro evaluation system for assessing drug dissolution considering physiological environment in nasal cavity. Pharmaceutics. 2022;14(11):2350. https:\/\/doi.org\/10.3390\/pharmaceutics14112350.","DOI":"10.3390\/pharmaceutics14112350"},{"issue":"4","key":"4153_CR62","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1023\/A:1016405506028","volume":"4","author":"WJ Addicks","year":"1987","unstructured":"Addicks WJ, Flynn GL, Weiner N. Validation of a flow-through diffusion cell for use in transdermal research. Pharm Res. 1987;4(4):337\u201341.","journal-title":"Pharm Res"},{"issue":"3","key":"4153_CR63","doi-asserted-by":"publisher","first-page":"231","DOI":"10.2217\/pmt-2017-0060","volume":"8","author":"SA Ryan","year":"2018","unstructured":"Ryan SA, Dunne RB. Pharmacokinetic properties of intranasal and injectable formulations of naloxone for community use: a systematic review. Pain Manag. 2018;8(3):231\u201345.","journal-title":"Pain Manag"},{"issue":"1","key":"4153_CR64","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1002\/bdd.2348","volume":"44","author":"A Haasbroek-Pheiffer","year":"2023","unstructured":"Haasbroek-Pheiffer A, Van Niekerk S, Van der Kooy F, Cloete T, Steenekamp J, Hamman J. In vitro and ex vivo experimental models for evaluation of intranasal systemic drug delivery as well as direct nose-to-brain drug delivery. Biopharm Drug Dispos. 2023;44(1):94\u2013112.","journal-title":"Biopharm Drug Dispos"},{"issue":"2","key":"4153_CR65","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/0091-6749(83)90518-3","volume":"72","author":"N Geurkink","year":"1983","unstructured":"Geurkink N. Nasal anatomy, physiology, and function. J Allergy Clin Immunol. 1983;72(2):123\u20138.","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"4153_CR66","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1080\/01926230600713475","volume":"34","author":"JR Harkema","year":"2006","unstructured":"Harkema JR, Carey SA, Wagner JG. The nose revisited: a brief review of the comparative structure, function, and toxicologic pathology of the nasal epithelium. Toxicol Pathol. 2006;34(3):252\u201369.","journal-title":"Toxicol Pathol"},{"key":"4153_CR67","doi-asserted-by":"publisher","unstructured":"Williams G, Suman JD. In vitro anatomical models for nasal drug delivery. Pharmaceutics. 2022;14(7):1353. https:\/\/doi.org\/10.3390\/pharmaceutics14071353.","DOI":"10.3390\/pharmaceutics14071353"},{"issue":"2","key":"4153_CR68","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.addr.2008.09.008","volume":"61","author":"RA Cone","year":"2009","unstructured":"Cone RA. Barrier properties of mucus. Adv Drug Deliv Rev. 2009;61(2):75\u201385.","journal-title":"Adv Drug Deliv Rev"},{"issue":"2","key":"4153_CR69","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.addr.2008.11.002","volume":"61","author":"SK Lai","year":"2009","unstructured":"Lai SK, Wang YY, Hanes J. Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues. Adv Drug Deliv Rev. 2009;61(2):158\u201371.","journal-title":"Adv Drug Deliv Rev"},{"issue":"1","key":"4153_CR70","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.ijpharm.2013.05.040","volume":"453","author":"HH Sigurdsson","year":"2013","unstructured":"Sigurdsson HH, Kirch J, Lehr CM. Mucus as a barrier to lipophilic drugs. Int J Pharm. 2013;453(1):56\u201364.","journal-title":"Int J Pharm"},{"key":"4153_CR71","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2021.691227","volume":"12","author":"FM Carlier","year":"2021","unstructured":"Carlier FM, de Fays C, Pilette C. Epithelial barrier dysfunction in chronic respiratory diseases. Front Physiol. 2021;12:691227.","journal-title":"Front Physiol"},{"key":"4153_CR72","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2023.123255","volume":"643","author":"A Sena","year":"2023","unstructured":"Sena A, Costa A, Bastos F, Pinto AC, Vitorino C, Nunes A, et al. Development of a buccal in vitro permeation method - exploring aQbD implementation. Int J Pharm. 2023;643:123255.","journal-title":"Int J Pharm"},{"key":"4153_CR73","doi-asserted-by":"publisher","unstructured":"Song J, Xu Z, Xie L, Shen J. Recent advances in studying in vitro drug permeation across mucosal membranes. Pharmaceutics. 2025;17(2):256. https:\/\/doi.org\/10.3390\/pharmaceutics17020256.","DOI":"10.3390\/pharmaceutics17020256"},{"key":"4153_CR74","unstructured":"European Medicines Agency. Guideline on the pharmacokinetic and clinical evaluation of modified release dosage forms [Internet]. London: European Medicines Agency; 2014. EMA\/CHMP\/EWP\/280\/96 Rev. 1. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-pharmacokinetic-and-clinical-evaluation-modified-release-dosage-forms_en.pdf. Accessed 6 Jul 2026."},{"issue":"4","key":"4153_CR75","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1007\/s13346-020-00891-5","volume":"12","author":"LA Keller","year":"2022","unstructured":"Keller LA, Merkel O, Popp A. Intranasal drug delivery: opportunities and toxicologic challenges during drug development. Drug Deliv Transl Res. 2022;12(4):735\u201357.","journal-title":"Drug Deliv Transl Res"},{"issue":"4","key":"4153_CR76","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s40262-024-01355-6","volume":"63","author":"TI Saari","year":"2024","unstructured":"Saari TI, Strang J, Dale O. Clinical pharmacokinetics and pharmacodynamics of naloxone. Clin Pharmacokinet. 2024;63(4):397\u2013422.","journal-title":"Clin Pharmacokinet"}],"container-title":["Pharmaceutical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-026-04153-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11095-026-04153-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-026-04153-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T15:54:47Z","timestamp":1791302087000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11095-026-04153-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,30]]},"references-count":76,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["4153"],"URL":"https:\/\/doi.org\/10.1007\/s11095-026-04153-w","relation":{},"ISSN":["0724-8741","1573-904X"],"issn-type":[{"value":"0724-8741","type":"print"},{"value":"1573-904X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,30]]},"assertion":[{"value":"15 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":1,"name":"Ethics","label":"Competing Interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This scientific publication reflects the views of the authors and should not be construed to represent FDA\u2019s views or policies.","order":2,"name":"Ethics","label":"Disclaimer","group":{"name":"EthicsHeading","label":"Declarations"}}]}}